Clinical Trial Update: Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of a tumor-derived heat shock protein 70 vaccine for breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HSP70 tumor-derived vaccine (heat shock protein 70 vaccine)

Snippet

Sponsor: UConn Health | Conditions: Breast Neoplasms | Phase 1, Phase 2 | Status: TERMINATED